Enrique Conterno

Type: Person
Name: Enrique Conterno
First reported Jul 25 2014 - Updated Jul 25 2014 - 1 reports

Eli Lilly's (LLY) CEO John Lechleiter on Q2 2014 Results - Earnings Call Transcript

OperatorLadies and gentlemen, thank you for standing by. Welcome to the Q 2014 earnings call. At this time, all participants are in a listen only mode. Later we will conduct a question-and-answer session. (Operator Instructions). As a reminder, this conference ... [Published Seeking Alpha - Jul 25 2014]
First reported Jul 07 2014 - Updated Jul 07 2014 - 1 reports

The Revolt Against Big Pharma's Astronomical Prices

Don't be caught off-guard. Drugmakers are facing a new mandate -- cut prices or be banned.Here's what's afoot. Health plans are increasingly refusing to cover certain drugs unless companies -- including Pfizer (NYSE: PFECVS Caremark, the nation's second-largest ... [Published Motley Fool - Jul 07 2014]
First reported Jun 30 2014 - Updated Jun 30 2014 - 1 reports

CHMP recommends Lilly/Boehringer's new insulin glargine product for approval in EU to treat type 1 and type 2 diabete

The Committee for Medicinal Products for Human Use (CHMP) issued a positive opinion recommending approval for the investigational compound LY2963016, a new insulin glargine product, for the treatment of type 1 and type 2 diabetes. The new insulin glargine ... [Published PharmaBiz - Jun 30 2014]
First reported Jun 27 2014 - Updated Jun 28 2014 - 1 reports

Lilly and Boehringer inch closer to challenging Lantus with EU nod

Eli Lilly ($LLY) and Boehringer Ingelheim have convinced European regulators to recommend their biosimilar of Sanofi's ($SNY) Lantus, the world's top-selling insulin, setting the stage for a near-term approval and launch once the reference product comes ... [Published FierceBiotech - Jun 27 2014]
First reported Jun 27 2014 - Updated Jun 27 2014 - 5 reports

European committee recommends approval of insulin biosimilar

The European Committee for Medicinal Products for Human Use, or CHMP, granted a positive opinion for the recommendation of LY2963016, a new insulin glargine product considered a biosimilar in Europe.“The CHMP’s recommendation brings us a step closer to ... [Published Orthopedics Today - Jun 27 2014]
First reported May 24 2014 - Updated May 24 2014 - 1 reports

EU grants marketing approval for Jardiance tabs to treat type 2 diabetes mellitus to improve glycemic control in adults

Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company announced that the European Commission granted marketing authorization for Jardiance (empagliflozin) tablets, a sodium glucose co-transporter 2 (SGLT2) inhibitor, for the treatment of ... [Published PharmaBiz - May 24 2014]
First reported Feb 27 2014 - Updated Feb 27 2014 - 1 reports

Lilly's phase III trial for once-weekly dulaglutide to treat type 2 diabetes achieves primary endpoint

Eli Lilly and Company, a global healthcare leader, has reported positive top-line results of the sixth AWARD (Assessment of Weekly AdministRation of LY2189265 in Diabetes) trial for once-weekly dulaglutide, an investigational, long-acting glucagon-like ... [Published PharmaBiz - Feb 27 2014]

More Content

All (12) | News (12) | Reports (0) | Blogs (0) | Audio/Video (0) | Fact Sheets (0) | Press Releases (0)
sort by: Date | Relevance
Eli Lilly's (LLY) CEO John Lechleiter on Q2 201... [Published Seeking Alpha - Jul 25 2014]
The Revolt Against Big Pharma's Astronomical Pr... [Published Motley Fool - Jul 07 2014]
CHMP recommends Lilly/Boehringer's new insulin ... [Published PharmaBiz - Jun 30 2014]
European committee recommends approval of insul... [Published Orthopedics Today - Jun 27 2014]
Lilly and Boehringer inch closer to challenging... [Published FierceBiotech - Jun 27 2014]
Lilly-BI Compound is First Biosimilar Insulin B... [Published Drug Discovery and Development - Jun 27 2014]
CHMP Recommends Lilly and Boehringer Ingelheim'... [Published PharmaceuticalProcessing - Jun 27 2014]
CHMP Recommends Lilly and Boehringer Ingelheim'... [Published Nasdaq - Jun 27 2014]
CHMP Recommends Lilly and Boehringer Ingelheim'... [Published Nasdaq - Jun 27 2014]
EU grants marketing approval for Jardiance tabs... [Published PharmaBiz - May 24 2014]
Lilly's phase III trial for once-weekly dulaglu... [Published PharmaBiz - Feb 27 2014]
Lilly to invest $700m for enhancing its global ... [Published Pharmaceutical Business Review - Nov 15 2013]
1
Content Volume
Document Volume
Network
Network
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.